The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes
Abstract
Chemotherapy dosing of the fluoropyrimidine 5-fluorouracil (5-FU) is currently based on body surface area. However, body surface area-based dosing has been associated with clinically significant pharmacokinetic variability, and as such, dosing based on body surface area may be of limited use. The clinical activity of 5-FU is modest at standard doses, and in general, dosing is limited by the safety profile, with myelosuppression and gastrointestinal toxicity being the most commonly observed side effects. Various strategies have been developed to enhance the clinical activity of 5-FU, such as biochemical modulation, alterations in scheduling of administration, and the use of oral chemotherapy. Studies that have shown an association between plasma concentration with toxicity and clinical efficacy have shown that pharmacokinetically guided dose adjustments can substantially improve the therapeutic index of 5-FU treatment. These studies have shown that only 20%-30% of patients treated with a 5-FU-based regimen have 5-FU levels that are in the appropriate therapeutic range--approximately 40%-60% of patients are underdosed and 10%-20% of patients are overdosed. To date, 5-FU drug testing has not been widely used because of the lack of a simple, fast, and inexpensive method. Recent advances in testing based on liquid chromatography-mass spectroscopy and a nanoparticle antibody-based immunoassay for 5-FU may now allow for routine monitoring of 5-FU in clinical practice. We review the data on pharmacokinetically guided dose adjustment of 5-FU and discuss the potential of this approach to advance therapeutic outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Cited by
Tonga, G. Y., Jeong, Y., Duncan, B., Mizuhara, T., Mout, R., Das, R., Kim, S. T., Yeh, Y.-C., Yan, B., Hou, S., et al. (2015) · Nature Chemistry · doi:10.1038/nchem.2284 · Cited by 497
Weiss, J. T., Dawson, J. C., Macleod, K. G., Rybski, W., Fraser, C., Torres-Sánchez, C., Patton, E. E., Bradley, M., Carragher, N. O., & Unciti-Broceta, A. (2014) · Nature Communications · doi:10.1038/ncomms4277 · Cited by 359
Tan, I. B., Ivanova, T., Lim, K. H., Ong, C. W., Deng, N., Lee, J., Tan, S. H., Wu, J., Lee, M. H., Ooi, C. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.042 · Cited by 357
On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology
Chou, D. B., Frismantas, V., Milton, Y., David, R., Pop-Damkov, P., Ferguson, D., MacDonald, A., Vargel Bölükbaşı, Ö., Joyce, C. E., Moreira Teixeira, L. S., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0495-z · Cited by 294
Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics
Paci, A., Veal, G., Bardin, C., Levêque, D., Widmer, N., Beijnen, J., Astier, A., & Chatelut, E. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.014 · Cited by 260
Metadata
- Authors
- Saif, M. W., Choma, A., Salamone, S. J., & Chu, E.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-18
- Volume
- 101
- Issue
- 22
- Pages
- 1543-1552
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2102290191
- Cited by
- 216
- References
- 1
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes. https://app.cochat.ai/papers/10.1093/jnci/djp328
- The paper
- Saif, M. W., Choma, A., Salamone, S. J., & Chu, E. (2009). Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djp328
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.